ATE123291T1 - Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente. - Google Patents

Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente.

Info

Publication number
ATE123291T1
ATE123291T1 AT88907884T AT88907884T ATE123291T1 AT E123291 T1 ATE123291 T1 AT E123291T1 AT 88907884 T AT88907884 T AT 88907884T AT 88907884 T AT88907884 T AT 88907884T AT E123291 T1 ATE123291 T1 AT E123291T1
Authority
AT
Austria
Prior art keywords
permeability
biologically active
killing
fragments
protein fragments
Prior art date
Application number
AT88907884T
Other languages
English (en)
Inventor
Peter Elsbach
Jerrold Weiss
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26770870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE123291(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ New York filed Critical Univ New York
Application granted granted Critical
Publication of ATE123291T1 publication Critical patent/ATE123291T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Noodles (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
AT88907884T 1987-08-11 1988-08-09 Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente. ATE123291T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8433587A 1987-08-11 1987-08-11
US22803588A 1988-08-05 1988-08-05

Publications (1)

Publication Number Publication Date
ATE123291T1 true ATE123291T1 (de) 1995-06-15

Family

ID=26770870

Family Applications (2)

Application Number Title Priority Date Filing Date
AT88907884T ATE123291T1 (de) 1987-08-11 1988-08-09 Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente.
AT94115703T ATE312844T1 (de) 1987-08-11 1988-08-09 Biologisch-aktive bakterizide/permeabilitätserhöhende proteinbruchstücke

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT94115703T ATE312844T1 (de) 1987-08-11 1988-08-09 Biologisch-aktive bakterizide/permeabilitätserhöhende proteinbruchstücke

Country Status (7)

Country Link
US (1) US5980897A (de)
EP (3) EP0652230B1 (de)
JP (1) JP3086685B2 (de)
AT (2) ATE123291T1 (de)
CA (1) CA1341525C (de)
DE (2) DE3853918T2 (de)
WO (1) WO1989001486A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US6265187B1 (en) 1989-02-14 2001-07-24 Incyte Pharmaceuticals, Inc. Recombinant endotoxin-neutralizing proteins
US6093801A (en) * 1989-02-14 2000-07-25 Incyte Pharmaceuticals, Inc. Recombinant analogs of bactericidal/permeability increasing protein
US5770694A (en) * 1990-08-13 1998-06-23 Incyte Pharmaceuticals, Inc. Genetically engineered BPI variant proteins
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
WO1992009621A1 (en) * 1990-12-03 1992-06-11 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5652211A (en) * 1991-02-11 1997-07-29 Biosynth S.R.L. Peptides for neutralizing the toxicity of Lipid A
SE468516B (sv) * 1991-06-14 1993-02-01 Kabigen Ab Nya polypeptider vilka kan utvinnas fraan tunntarmen och deras anvaendning
WO1993023434A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
US6274348B1 (en) 1992-05-19 2001-08-14 Xoma Corporation Methods for the preparation of positively charged proteins
US5915378A (en) * 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US6024090A (en) 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5873358A (en) * 1993-01-29 1999-02-23 Aradigm Corporation Method of maintaining a diabetic patient's blood glucose level in a desired range
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US6131567A (en) * 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US5970973A (en) * 1993-01-29 1999-10-26 Aradigm Corporation Method of delivering insulin lispro
US5743250A (en) 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
US5420019A (en) 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5488034A (en) * 1993-02-02 1996-01-30 Xoma Corporation Pharmaceutical composition comprising BPI proteins
CA2157927C (en) * 1993-03-12 1999-03-30 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein produc ts
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
CA2146667A1 (en) 1993-08-18 1995-02-23 Adolf Hoess Lipopolysaccharide-binding and neutralizing peptides
DK0759774T3 (da) * 1993-09-22 2002-10-07 Xoma Technology Ltd Fremgangsmåde til behandling af gram-negativ bakteriel infektion ved indgivelse af baktericidt/permeabilitet-forøgende (BPI) proteinprodukt og antibiotikum
CA2181164C (en) * 1994-01-14 2008-01-08 Arnold Horwitz Anti-gram-positive bacterial methods and materials
US5643875A (en) * 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5830860A (en) * 1994-03-24 1998-11-03 Regents Of The University Of Minnesota Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5932544A (en) 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
WO1997004008A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
ATE234111T1 (de) * 1996-05-23 2003-03-15 Xoma Technology Ltd Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
CA2255865C (en) 1996-05-24 2008-10-14 The Regents Of The University Of Minnesota Synthesis of soluble beta-sheet forming peptides
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6153584A (en) * 1999-04-01 2000-11-28 Levy; Ofer Therapeutic uses of BPI protein products in BPI-deficient humans
US7041644B2 (en) 1999-04-01 2006-05-09 Xoma Technology Therapeutic uses of BPI protein products in BPI-deficient humans
AU2001252246A1 (en) * 2000-04-05 2001-10-23 Syngenta Participations Ag Therapeutically active proteins in plants
KR100351829B1 (ko) * 2000-09-26 2002-09-11 엘지전자 주식회사 디지털 통신 시스템
JP2004517865A (ja) * 2000-12-01 2004-06-17 ゾーマ テクノロジー リミテッド Ｂｐｉタンパク質産物またはｂｐｉインヒビターを使用する、周皮細胞増殖の調節
US7056514B2 (en) 2002-02-20 2006-06-06 Regents Of The University Of Minnesota Partial peptide mimetics and methods
EP1741440A1 (de) * 2005-07-08 2007-01-10 Mellitus S.L. Verwendung von BPI-proteine zur Behandlung von stoffwechselbedingten Erkrankungen und Herzkreislaufstörungen
EP2694084B1 (de) 2011-04-05 2016-03-23 Dana-Farber Cancer Institute, Inc. Bpi und seine analoge als strahlungsabschwächer und strahlungsschutz

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126257A (en) * 1986-11-26 1992-06-30 Cornell Research Foundation Antimicrobial proteins, compositions containing same and uses thereof
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof

Also Published As

Publication number Publication date
EP0375724A1 (de) 1990-07-04
DE3856588D1 (de) 2006-01-19
EP0375724B1 (de) 1995-05-31
DE3853918D1 (de) 1995-07-06
DE3853918T2 (de) 1996-02-08
EP0652230B1 (de) 2005-12-14
JP3086685B2 (ja) 2000-09-11
EP1659132A1 (de) 2006-05-24
US5980897A (en) 1999-11-09
JP2000139484A (ja) 2000-05-23
EP0375724A4 (en) 1991-12-11
EP0652230A1 (de) 1995-05-10
DE3856588T2 (de) 2006-09-07
WO1989001486A1 (en) 1989-02-23
CA1341525C (en) 2007-04-17
ATE312844T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
DE3853918D1 (de) Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente.
DE3886060D1 (de) Vorläuferprotein des APC-Polypeptids, dafür codierende DNA und diagnostische Verwendung der DNA und des Proteins.
FI974432A7 (fi) Grampositiivisten bakteerien käyttö rekombinanttiproteiinien ilmentämiseksi
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
DE3884529D1 (de) Leader-anteile zur produktion von rekombinanten proteinen.
NO874908D0 (no) Antimikrobielle proteiner, preparater inneholdende disse og anvendelse derav.
AU9127591A (en) Biologically active bactericidal/permeability-increasing protein fragments
AU637139B2 (en) Gm-csf protein, its derivatives, the preparation of proteins of this type, and their use
IL80562A0 (en) Recombinant human lysozyme,its preparation by recombinant dna technology and pharmaceutical compositions containing it
FI885237A7 (fi) Menetelmä yhdistelmä-E. colissa ilmennetyn P. falciparum-CS-proteiinir okotteen eristämiseksi ja puhdistamiseksi
SE8505920D0 (sv) New protein and its use
FI893932A7 (fi) Funktionaalisten homologisten ja heterologisten proteiinien ilmaiseminen E.colin ja muiden gram-negatiivisten bakteerien ulkomembraanilla
FI885025A0 (fi) Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning.
EP0723016A3 (de) Leukocyten-aktivierender Faktor
FI901764A7 (fi) Synteettinen DNA-sekvenssi, joka koodaa ihmisen insuliinin kaltaista k asvutekijää II
FI881870A7 (fi) L-fenyylialaniinin valmistus rekombinanttibakteerien avulla.
FI924835L (fi) Pectinatus-bakteerin proteiinifragmentteja
NO875477D0 (no) Rekombinant alveolaert overflateaktivt protein.
IT8721455A0 (it) Composizioni farmaceutiche per la terapia di stati fisiopatologici ad accresciuto catabolismo proteico.
IT8621261A0 (it) Composizioni farmaceutiche per la terapia di stati fisiopatologici ad accresciuto catabolismo proteico.
NZ212039A (en) Vaccine containing bacteria capable of living on protein foreign to warm-blooded animals
ITMI961647A1 (it) Uso di particolari specie di batteri lattici o loro miscele per l'autopurificazione fisiologica della vagina e composizioni farmaceutiche che le contengono.
ATE95238T1 (de) Leader-anteile zur produktion von rekombinanten proteinen.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee